Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ
Authors:
Open Access
- 24 June 2023
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (13) , 11181-11191
Abstract
Purpose: The purpose of this study is to compare and analyze the clinicopathological characteristics and prognosis of patients with invasive ductal carcinoma coexisting with ductal carcinoma in situ (IDC-DCIS) and invasive ductal carcinoma (IDC) in triple-negative breast cancer (TNBC), and to explore the factors affecting the prognosis, so as to provide new ideas for clinical diagnosis and treatment of these patients. Methods: The patients with TNBC underwent surgery in the Department of Breast Surgery of Harbin Medical University Cancer Hospital from October 2012 to December 2018 were retrospectively analyzed and divided into IDC-DCIS group and IDC group. The clinicopathological characteristics and prognosis of the two groups were compared. P < 0.05 was considered statistically significant. Results: A total of 358 patients were enrolled. There were significant differences in age (P = 0.002), family history (P = 0.016), menopausal status (P = 0.003), KI-67% (P < 0.001), lymphovascular invasion (P = 0.010), histologic grade of IDC (P < 0.001) and multifocal (P < 0.001) between the two groups. The disease-free survival (DFS) of the IDC-DCIS group was better than that of the IDC group (the 5-year DFS was 87.9% vs. 82.6%, P = 0.045), but the overall survival (OS) of the two groups was not statistically significant (the 5-year OS was 96.2% vs. 96.0%, P = 0.573). In addition, the coexistence of DCIS (P = 0.030), lymph node pathologic stage (P = 0.001), tumor location (P = 0.011), and adjuvant chemotherapy (P < 0.001) were independent prognostic factors for DFS. Conclusion: In TNBC, the IDC-DCIS group had less invasive biological characteristics. The DFS of the IDC-DCIS group was better than that of the IDC group, but there was no statistical difference in OS between the two groups. In addition, the coexistence of DCIS, lymph node stage, tumor location and adjuvant chemotherapy may be independent prognostic factors for DFS.Keywords
This publication has 38 references indexed in Scilit:
- Breast cancer classification by proteomic technologies: Current state of knowledgeCancer Treatment Reviews, 2014
- Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor–product relationshipJournal of Clinical Pathology, 2013
- Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospectsTherapeutic Advances in Medical Oncology, 2013
- Influence of the in situ component in 389 infiltrating ductal breast carcinomasBreast Cancer, 2012
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- PIK3CA Mutations in In situ and Invasive Breast CarcinomasCancer Research, 2010
- Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancerBritish Journal of Cancer, 2010
- Tumour location is not an independent prognostic factor for survival following a diagnosis of breast cancerThe Breast, 2009
- Tumor Location of the Lower-Inner Quadrant Is Associated with an Impaired Survival for Women With Early-Stage Breast CancerAnnals of Surgical Oncology, 2006
- Influence of tumor location on breast cancer prognosisInternational Journal of Cancer, 2003